Johnson & Johnson
DUS:JNJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Johnson & Johnson
DUS:JNJ
|
US |
|
Beijing Dinghan Technology Group Co Ltd
SZSE:300011
|
CN |
Revenue Breakdown
Breakdown by Geography
Johnson & Johnson
|
Total Revenue:
94.2B
USD
|
|
United States Plans:
50.3B
USD
|
|
Non-Us:
38.5B
USD
|
Breakdown by Segments
Johnson & Johnson
|
Total Revenue:
94.2B
USD
|
|
Innovative Medicine:
57B
USD
|
|
Medtech:
31.9B
USD
|
|
Darzalex:
11.7B
USD
|
|
Stelara:
10.4B
USD
|
|
General:
5.4B
USD
|
|
Electrophysiology:
5.3B
USD
|
|
Advanced:
4.5B
USD
|
|
Invega Sustenna/Xeplion/Trinza/Trevicta:
4.2B
USD
|
|
Contact Lenses/Other:
3.7B
USD
|
|
Tremfya:
3.7B
USD
|
|
Trauma:
3B
USD
|
|
Imbruvica:
3B
USD
|
|
Erleada:
3B
USD
|
|
Spine,Sports & Other:
2.9B
USD
|
|
Xarelto:
2.4B
USD
|
|
Simponi/Simponi Aria:
2.2B
USD
|
|
Opsumit:
2.2B
USD
|
|
Uptravi:
1.8B
USD
|
|
Prezista/Prezcobix/Rezolsta/Symtuza:
1.7B
USD
|
|
Hips:
1.6B
USD
|
|
Remicade:
1.6B
USD
|
|
Knees:
1.5B
USD
|
|
Abiomed:
1.5B
USD
|
|
Surgical:
1.4B
USD
|
|
Edurant/Rilpivirine:
1.3B
USD
|
|
Other:
1.2B
USD
|
|
Other Neuroscience:
1.2B
USD
|
|
Spravato:
1.1B
USD
|
|
Carvykti:
963m
USD
|
|
Other Oncology:
931m
USD
|
|
Concerta/Methylphenidate:
641m
USD
|
|
Zytiga/Abiraterone Acetate:
631m
USD
|
|
Shockwave Medical, Inc:
564m
USD
|
|
Tecvayli:
549m
USD
|
|
Other Cardiovascular:
380m
USD
|
|
Other Pulmonary Hypertension:
281m
USD
|
|
Other Infectious Diseases:
214m
USD
|
|
Covid-19:
198m
USD
|
|
Other Immunology:
3m
USD
|